Herantis Pharma Oyj

Helsinki Stock Exchange HRTIS.HE

Herantis Pharma Oyj Shares (Diluted, Weighted) for the year ending December 31, 2023: 17,195,000

Herantis Pharma Oyj Shares (Diluted, Weighted) is 17,195,000 for the year ending December 31, 2023, a 17.34% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Herantis Pharma Oyj Shares (Diluted, Weighted) for the year ending December 31, 2022 was 14,654,149, a 43.60% change year over year.
Herantis Pharma Oyj Shares (Diluted, Weighted) for the year ending December 31, 2021 was 10,205,000, a 31.26% change year over year.
Herantis Pharma Oyj Shares (Diluted, Weighted) for the year ending December 31, 2020 was 7,774,437, a 26.51% change year over year.
Herantis Pharma Oyj Shares (Diluted, Weighted) for the year ending December 31, 2019 was 6,145,343, a 24.95% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

Helsinki Stock Exchange: HRTIS.HE

Herantis Pharma Oyj

CEO	Dr. Antti Vuolanto D.Sc. (Tech)
IPO Date	June 11, 2014
Location	Finland
Headquarters	Bertel Jungin Aukio 1
Employees	11
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.

Key trends

Past 5 years